Literature DB >> 11913715

Acetaminophen-induced immunosuppression associated with hepatotoxicity in mice.

K Ueno1, K Yamaura, T Nakamura, T Satoh, S Yano.   

Abstract

We investigated the influence of acetaminophen (APAP), an analgesic and hepatotoxic agent, on the immune system in mice. The activity of serum glutamic-pyruvic transaminase was markedly increased by about 200 fold compared to that of the vehicle control following intraperitoneal injection of 400 mg/kg of APAP. In vivo antibody-producing responses to SRBC was significantly inhibited by APAP in a dose-dependent manner, while in vivo T cell-independent antibody-producing responses to TNP-Ficoll was not inhibited. The addition of thymocytes from APAP-treated mice suppressed the response to SRBC in vitro. Thymocyte blastogenesis following mitogenic stimulation with concanavalin A was also inhibited by injection of APAP. The delayed-type hypersensitivity response and mixed lymphocyte reaction, which are used to evaluate cell-mediated immunity, were also significantly reduced after treatment with APAP. These results indicate that APAP suppresses the humoral and cell-mediated immune responses at a dose that causes liver injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11913715

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  4 in total

1.  Blood gene expression markers to detect and distinguish target organ toxicity.

Authors:  Christina Umbright; Rajendran Sellamuthu; Shengqiao Li; Michael Kashon; Michael Luster; Pius Joseph
Journal:  Mol Cell Biochem       Date:  2009-09-26       Impact factor: 3.396

2.  Revision of ICH S8 Needed?

Authors:  Jan Willem Van Der Laan
Journal:  Front Toxicol       Date:  2022-04-25

Review 3.  Is fever suppression involved in the etiology of autism and neurodevelopmental disorders?

Authors:  Anthony R Torres
Journal:  BMC Pediatr       Date:  2003-09-02       Impact factor: 2.125

4.  Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials.

Authors:  Anne M C M Doedée; Greet J Boland; Jeroen L A Pennings; Arja de Klerk; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Henk van Loveren; Riny Janssen
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.